Pharmacokinetic problems in clinical practice - Role of drug transporters;Pharmakokinetische probleme in der praxis - Rolle von arzneimitteltransportern

Deutsche Medizinische Wochenschrift

Volumn 134, Issue 8, 2009, Pages 345-356

  Rosskopf, Dieter ^a   Kroemer, H K ^a   Siegmund, W ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

ABC transporter; CYP enzymes; Drug interactions; Drug metabolism; Drug transport; SLCO1B1

Indexed keywords

AMOXICILLIN; ANTIHISTAMINIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BREAST CANCER RESISTANCE PROTEIN; CARBAMAZEPINE; CLARITHROMYCIN; CYCLOSPORIN; CYTOCHROME P450; DESIPRAMINE; DEXTROMETHORPHAN; DIGOXIN; EFAVIRENZ; FLUVOXAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MOCLOBEMIDE; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; OMEPRAZOLE; PHENPROCOUMON; PHENYTOIN; PROTEINASE INHIBITOR; PROTON PUMP INHIBITOR; QUINIDINE; RIFAMPICIN; THEOPHYLLINE; THIORIDAZINE; UNINDEXED DRUG; VANCOMYCIN; VERAPAMIL; XENOBIOTIC AGENT; CARRIER PROTEIN;

BACTERIAL ENDOCARDITIS; CLINICAL PRACTICE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG TRANSFORMATION; DRUG TRANSPORT; FOOD DRUG INTERACTION; HEART ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HELICOBACTER INFECTION; HUMAN; MAXIMUM PLASMA CONCENTRATION; MYOPATHY; NEPHROTOXICITY; PHARMACODYNAMICS; PHARMACOKINETICS; PROTEIN EXPRESSION; REVIEW; SINUSITIS; TACHYCARDIA; ADULT; AGED; BIOAVAILABILITY; BIOTRANSFORMATION; CASE REPORT; CHEMICALLY INDUCED DISORDER; DRUG INTERACTION; FEMALE; GRAPEFRUIT; HYPERICUM; INTESTINE ABSORPTION; MALE; METABOLISM; MIDDLE AGED; MUSCLE DISEASE; PHYSIOLOGY;

ADULT; AGED; ARRHYTHMIAS, CARDIAC; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; CITRUS PARADISI; DRUG INTERACTIONS; FEMALE; FOOD-DRUG INTERACTIONS; HUMANS; HYPERICUM; INTESTINAL ABSORPTION; MALE; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; MUSCULAR DISEASES; PHARMACOKINETICS; XENOBIOTICS;

EID: 59849088423     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0028-1124005     Document Type: Review

References (34)

1. Armitage J. The safety of statins in clinical practice. Lancet 2007; 370 (9601): 1781-1790
2. Bailey DG, Spence JD, Edgar B, Bayliff CD, Arnold JM. Ethanol enhances the hemodynamic effects of felodipine. Clin Invest Med 1989; 12 (6): 357-362 (Pubitemid 20014984)
3. Bent S. Herbal medicine in the United States: review of efficacy, safety, and regulation: grand rounds at University of California, San Francisco Medical Center. J Gen Intern Med 2008; 23 (6): 854-859
4. Bernsdorf A, Giessmann T, Modess C et al. Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms. Br J Clin Pharmacol 2006; 61 (4): 440-450
5. Dietrich CG, Geier A, Oude Elferink RPJ. ABC of oral bioavailability: transporters as gatekeepers in the gut. Gut 2003; 52 (12): 1788-1795 (Pubitemid 37510405)
6. Drescher S, Glaeser H, Mürdter T et al. P-glycoprotein-mediated intestinal and biliary digoxin transport in humans. Clin Pharmacol Ther 2003; 73 (3): 223-231 (Pubitemid 36269673)
7. Dresser GK, Schwarz UI, Wilkinson GR, Kim RB. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clin Pharmacol Ther 2003; 73 (1): 41-50 (Pubitemid 36158485)
8. Dürr D, Stieger B, Kullak-Ublick GA et al. St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 2000; 68 (6): 598-604 (Pubitemid 32059985)
9. Fromm MF, Kauffmann HM, Fritz P et al. The effect of rifampin treatment on intestinal expression of human MRP transporters. Am J Pathol 2000; 157 (5): 1575-1580 (Pubitemid 30943214)
10. Fromm MF, Kim RB, Stein CM, Wilkinson GR, Roden DM. Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 1999; 99 (4): 552-557 (Pubitemid 29061872)
11. Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 2001; 276 (18): 14581-14587 (Pubitemid 37373327)
12. Giessmann T, May K, Modess C et al. Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. Clin Pharmacol Ther 2004; 76 (3): 192-200 (Pubitemid 39221793)
13. Glaeser H, Bailey DG, Dresser GK et al. Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther 2007; 81 (3): 362-370 (Pubitemid 46364477)
14. Greiner B, Eichelbaum M, Fritz P et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999; 104 (2): 147-153
15. Hall SD, Wang Z, Huang S et al. The interaction between St John's wort and an oral contraceptive. Clin Pharmacol Ther 2003; 74 (6): 525-535 (Pubitemid 37521996)
16. Ho RH, Kim RB. Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 2005; 78 (3): 260-277 (Pubitemid 41254111)
17. Kirby BJ, Unadkat JD. Grapefruit juice, a glass full of drug interactions? Clin Pharmacol Ther 2007; 81 (5): 631-633
18. Kivistö KT, Niemi M, Fromm MF. Functional interaction of intestinal CYP3A4 and P-glycoprotein. Fundam Clin Pharmacol 2004; 18 (6): 621-626 (Pubitemid 39564261)
19. König J, Seithel A, Gradhand U, Fromm MF. Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch Pharmacol 2006; 372 (6): 432-443
20. Leahey EB, Reiffel JA, Drusin RE et al. Interaction between quinidine and digoxin. JAMA 1978; 240 (6): 533-534
21. Linton KJ. Structure and function of ABC transporters. Physiology 2007; 22: 122-130
22. Mai I, Krüger H, Budde K et al. Hazardous pharmacokinetic interaction of Saint John's wort (Hypericum perforatum) with the immunosuppressant cyclosporin. Int J Clin Pharmacol Ther 2000; 38 (10): 500-502 (Pubitemid 30765595)
23. Marchetti S, Mazzanti R, Beijnen JH, Schellens JHM. Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist 2007; 12 (8): 927-941 (Pubitemid 47359135)
24. Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol 2007; 49 (23): 2231-2237 (Pubitemid 46856819)
25. Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet 2002; 360 (9340): 1155-1162
26. Ray WA, Murray KT, Meredith S et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 2004; 351 (11): 1089-1096 (Pubitemid 39167513)
27. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004; 350 (10): 1013-1022
28. Schwarz UI, Büschel B, Kirch W. Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception. Br J Clin Pharmacol 2003; 55 (1): 112-113 (Pubitemid 36110847)
29. The SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy - A Genomewide Study. N Engl J Med 2008; 359 (8): 789-799
30. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003; 289 (13): 1681-1690
31. Wang Z, Hamman MA, Huang S, Lesko LJ, Hall SD. Effect of St John's wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther 2002; 71 (6): 414-420 (Pubitemid 34701348)
32. Westphal K, Weinbrenner A, Giessmann T et al. Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein. Clin Pharmacol Ther 2000; 68 (1): 6-12 (Pubitemid 30609821)
33. Westphal K, Weinbrenner A, Zschiesche M et al. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Clin Pharmacol Ther 2000; 68 (4): 345-355 (Pubitemid 30803523)
34. Xie H, Kim RB. St John's wort-associated drug interactions: short-term inhibition and long-term induction? Clin Pharmacol Ther 2005; 78 (1): 19-24